Acrivon Therapeutics, Inc.
ACRV
$2.57
$0.041.58%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -18.23M | -21.01M | -19.68M | -22.83M | -22.44M |
| Total Depreciation and Amortization | 349.00K | 335.00K | 311.00K | 303.00K | 251.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.14M | 4.01M | 3.68M | 3.05M | 2.70M |
| Change in Net Operating Assets | 1.47M | 52.00K | -3.85M | 2.12M | 2.16M |
| Cash from Operations | -12.28M | -16.61M | -19.54M | -17.36M | -17.32M |
| Capital Expenditure | -899.00K | -493.00K | -58.00K | -827.00K | -989.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 6.81M | 19.94M | 19.27M | 15.24M | 17.00M |
| Cash from Investing | 5.91M | 19.45M | 19.21M | 14.41M | 16.01M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 0.00 | 0.00 | 1.00K | 0.00 | 0.00 |
| Repurchase of Common Stock | -117.00K | -97.00K | -344.00K | -647.00K | -1.20M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 0.00 | -307.00K |
| Cash from Financing | -117.00K | -97.00K | -343.00K | -647.00K | -1.50M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -6.49M | 2.74M | -664.00K | -3.60M | -2.82M |